Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Influenza Clinical Trial

Official title:

A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05895955
• Other study ID #: TetraFluvac TF vaccine
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: November 4, 2023
• Est. completion date: July 31, 2025

Study information

• Verified date: March 2024
• Source: Mahidol University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is aim to evaluate the safety and immunogenicity of one dose TetraFluvac TF vaccine (15 μg HA per strain per dose) of the GPO seasonal quadrivalent inactivated split virion influenza vaccine in healthy adults aged 18 years and above over 90 days post-injection.

Description:

This is a double blind randomized study consisting of two phases - Phase I and Phase II.

Phase I of the study A total of 40 healthy participants aged 18 years and above will be enrolled (1:1 ratio, 20 TetraFluvac TF vaccine and 20 Vaxigrip vaccine (Commercially available seasonal quadrivalent split, manufactured by Sanofi Pasteur, Ltd. France)

Phase II of the study A total of 250 healthy participants will be enrolled (4:1 ratio, 200 TetraFluvac TF vaccine and 50 Vaxigrip vaccine (Commercially available seasonal quadrivalent split , manufactured by Sanofi Pasteur, Ltd. France) One dose of the TetraFluvac TF or Commercially available seasonal quadrivalent split vaccine for Southern Hemisphere in 2023 will be given 0.5 ml by intramuscular route.

Total follow-up is 90 days.

The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm. After vaccination participants will remain at the clinic for at least 30 minutes to observe for any reactogenicity after immunization.

Blood specimens for immune response will be collected on Day 0 prior to vaccination, Day 28, Day 60, and day 90.

Blood specimen for safety will be collected Day 28 for participants Phase I only for clinical hematology and chemistry.

A DSMB, composed of at least three independent members with expertise in vaccine clinical trials, will be convened to provide additional safety oversight. In Phase I, the DSMB will meet to review all safety profiles of 28 days after immunization. After completing Day 7 of phase I with no safety concern, the screening for phase II can be started. However, the vaccination of phase II will occur after the recommendation of the DSMB.There should be no safety concerns from DSMB meeting for continue Phase II. In Phase II, the DSMB will meet to review all safety profiles after vaccination of 100 participants for completion of Phase II.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 290
• Est. completion date: July 31, 2025
• Est. primary completion date: March 25, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged 18 years and above

2. Having Thai ID card or equivalent

3. Able to read and provide written informed consent prior to performance of any study-specific procedure

4. Healthy as defined by no clinically significant acute medical condition, and no chronic medical condition that has not been controlled within 90 days of randomization, as determined by medical history, physical examination, screening laboratory test results, and clinical assessment of the investigator.

5. All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination)

Exclusion Criteria:

1. Known history of egg allergy

2. Having had recently influenza infection confirmed as H1N1, H3N2, or Flu B within 3 months preceding enrollment to the trial

3. Vaccination against influenza in the past 6 months preceding enrollment to the trial

4. History of bronchial asthma, chronic lung diseases, chronic rhinitis

5. History of immunodeficiency state

6. History of immunosuppression < 6 months prior to immunization

7. History of anaphylactic or other allergic reactions to influenza vaccine or any vaccine component or excipient (e.g. gentamicin or thimerosal)

8. Acute infectious with fever > 38 degree Celsius and noninfectious diseases (within 72 hours) preceding enrollment in the trial

9. The participants who have been taking immunoglobulin products or have had a blood transfusion during past 3 months before the beginning of the experiment

10. Participation in other research study

11. Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding

12. Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

13. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled, or could interfere with the evaluation of the vaccine

14. Employee of any person employed by the Sponsor, the contract research organization (CRO), the PI, study site personnel, or site.

15. Any test for HIV, HBsAg, Hep C antibody shows positive results with clinically significance

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• TetraFluvac TF vaccine
The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine [A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus] produced by The Government Pharmaceutical Organization (GPO), Thailand. Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (µg) hemagglutinin (HA) per 0.5 ml dose (15 µg HA per strain per dose), to be administered by intramuscular (IM) injection.
• Vaxigrip vaccine
Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine [A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France. Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (µg) hemagglutinin (HA) per 0.5 ml dose (15 µg HA per strain per dose), to be administered by intramuscular (IM) injection.

Locations

Country	Name	City	State
Thailand	Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University	Bangkok

Sponsors (2)

Lead Sponsor	Collaborator
Mahidol University	The Government Pharmaceutical Organization (GPO) Bangkok, Thailand

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	30-minutes after vaccination
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 1
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 2
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 3
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 4
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 5
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 6
Primary	Number and percentage of Solicited local adverse events post-vaccination.	Frequency of solicited reportable local adverse events (pain or tenderness, limitation arm movement, erythema, swelling or induration)	day 7
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	30-minutes after vaccination
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 1
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 2
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 3
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 4
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 5
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 6
Primary	Number and percentage of Solicited systemic adverse events post-vaccination.	Frequency of solicited reportable systemic adverse events (fever, chill, headache, rhinorrhea, fatigue or malaise, myalgia, arthralgia, rash, nausea or vomiting, diarrhea)	day 7
Primary	Number and percentage of participants with unsolicited adverse events	All unsolicited adverse events during 90 days will be analysed in terms of number and percentage and relationship to study vaccine; Number and percentage of participants with unsolicited adverse events	day 0 up to day 90
Primary	Number and percentage of participants with AESI	Number and percentage of participants with AESI	day 0 up to day 90
Primary	Number and percentage of participants with Medically-Attended Adverse Event	Number and percentage of participants with Medically-Attended Adverse Event	day 0 up to day 90
Primary	Number and percentage of participants with Serious Adverse Event	Number and percentage of participants with Serious Adverse Event	day 0 up to day 90
Secondary	Antihemagglutinin antibody titer changed from baseline.	Seroconversion is defined as a 4-fold rise in HI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of =1:40.	day 28
Secondary	Antihemagglutinin antibody titer changed from baseline.	Seroconversion is defined as a 4-fold rise in HI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of =1:40.	day 60
Secondary	Antihemagglutinin antibody titer changed from baseline.	Seroconversion is defined as a 4-fold rise in HI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of =1:40.	day 90
Secondary	Geometric mean of immune response changed from baseline	The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment	day 28
Secondary	Geometric mean of immune response changed from baseline	The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment	day 60
Secondary	Geometric mean of immune response changed from baseline	The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment	day 90